Please login to the form below

Not currently logged in
Email:
Password:

pantoprazole

This page shows the latest pantoprazole news and features for those working in and with pharma, biotech and healthcare.

Pfizer settles US Protonix lawsuit for $785m

Pfizer settles US Protonix lawsuit for $785m

over-charged Medicaid for Protonix (pantoprazole), failing to offer the federal government the same discounts it was offering to private customers.

Latest news

  • Pfizer 2014 guidance threatened by Celebrex competition Pfizer 2014 guidance threatened by Celebrex competition

    The early onset of generic competition to Celebrex comes after a torrid time for Pfizer in terms of patent losses, with cholesterol lowerer Lipitor (atorvastatin), gastrointestinal medicine Protonix (pantoprazole), Viagra (sildenafil)

  • Teva defends Copaxone from Dutch patent challenge Teva defends Copaxone from Dutch patent challenge

    Maintaining Copaxone revenues is particularly important for Teva after it was ordered to pay $1.6bn in compensation to Pfizer and Takeda for infirming the patent on their Protonix (pantoprazole) gastrointestinal

  • Takeda expands Latin American footprint

    These will be ulcer treatments Zurcal (pantoprazole) and Riopan (Magaldrate Dimeticone), the anti-inflammatory Faktu (Policresulen, Cinchocaine hydrochloride) and Albothyl (Policresulen), a gynaecology product.

  • Pfizer sales dip as net income surges in Q2 Pfizer sales dip as net income surges in Q2

    from the spin-out of Zoetis and a litigation settlement with Teva and Sun Pharmaceutical Industries for patent infringement of Protonix (pantoprazole) fell 5 per cent.

  • Teva and Sun pay dearly for 'at-risk' generic Protonix launch

    The settlement marked the end of almost a decade of litigation over the intellectual property for Protonix (pantoprazole), and is the first time that generic pharma companies have been punished for ... Teva and Sun took a risk in 2007 and 2008 when they

More from news
Approximately 1 fully matching, plus 28 partially matching documents found.

Latest Intelligence

  • Pharma deals during June 2013 Pharma deals during June 2013

    Top of the table is the patent settlement between Pfizer/ Takeda and Teva/ Sun Pharmaceutical for the launch of generic versions of Protonix (the proton pump inhibitor, pantoprazole) in 2007 ahead

  • Interview: Trevor Smith, Takeda Interview: Trevor Smith, Takeda

    For Nycomed this meant loss of exclusivity (LOE) on its blockbuster gastroinestinal drug pantoprazole and the consequent need to reorganise its business.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics